RecruitingNCT07115017

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

Investigation of Inflammation Using [18F]FZTA

Sponsor

Washington University School of Medicine

Enrollment

80 participants

Start Date

Aug 22, 2025

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis

Summary

This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This research study is testing a new experimental PET scan tracer called [18F]-FZTA to see if it can detect brain inflammation. It will be used in both healthy younger adults and people with multiple sclerosis (MS) to understand how well the tracer works. **You may be eligible if...** - You are 18 or older - You are a healthy adult, OR you have been diagnosed with multiple sclerosis - You are able to give written consent and lie still in a scanner **You may NOT be eligible if...** - You are allergic to the tracer or its ingredients - You cannot undergo PET, CT, or MRI scans (e.g., due to implanted devices) - You have severe claustrophobia - You are pregnant or breastfeeding - You are currently receiving radiation therapy - You have had a significant heart event (heart attack, stroke, irregular heart rhythm) in the last 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F] FZTA

Participants will receive a single intravenous bolus injection of 7 ± 20% milliCurie (mCi) of the investigational radiotracer \[18F\]-FZTA. A PET-certified medical professional will prepare and administer the \[18F\]-FZTA. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 7+20% mCi of \[18F\]-FZTA followed by a 10 mL 0.9% sodium chloride (normal saline) flush.

Locations(1)

Washington University in St. Louis

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07115017

Related Trials

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT027842101 location

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

NCT053577811 location

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

NCT000012481 location

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT058494671 location

Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)

NCT067952301 location